Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
Completed · Phase 2/Phase 3
Conditions studied: Major Depressive Disorder
In brief
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD. The primary prediction was that LCn-3 fatty acid supplementation would dose-dependently increase prefrontal cortical functional activation during sustained attention and increase regional biochemical indices of cortical metabolism and integrity concentrations in association with reductions in depressive symptoms.
Key facts
- Study ID
- NCT00511810
- Run by
- University of Cincinnati
- People needed
- 20
- Starts
- 2007-08-01
- Expected to finish
- 2011-03-01
- Last updated by the study team
- 2016-05-27
Who can join
Age: 12 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Cincinnati — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.